Login / Signup

Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients.

Daniel BoakyeLina JansenNiels HalamaJenny Chang-ClaudeMichael HoffmeisterHermann Brenner
Published in: Therapeutic advances in medical oncology (2021)
EDChemo is common in stage III colon cancer patients receiving chemotherapy and more than half of the cases of EDChemo and dose reduction are due to adverse treatment effects. Further research should address the potential for reducing EDChemo and dose reduction rates by close monitoring of patients for early signs and enhanced management of adverse effects, especially gastrointestinal events.
Keyphrases